Back to Search Start Over

First year of pre-exposure prophylaxis implementation in France with daily or on-demand tenofovir disoproxil fumarate/emtricitabine.

Authors :
Siguier, M
Mera, R
Pialoux, G
Ohayon, M
Cotte, L
Valin, N
Ghosn, J
Cua, E
Pintado, C
Chas, J
Barriere, G
Durand, F
Molina, J M
Source :
Journal of Antimicrobial Chemotherapy (JAC); Sep2019, Vol. 74 Issue 9, p2752-2758, 7p
Publication Year :
2019

Abstract

<bold>Background: </bold>In January 2016, the French Medicine Agency initiated a Temporary Recommendation for Use (TRU) to allow the use of oral intake of tenofovir disoproxil fumarate and emtricitabine for pre-exposure prophylaxis (PrEP) in adults at high risk of HIV. We report the results of the first year of PrEP implementation in France.<bold>Methods: </bold>Data were collected by physicians using a secured web subject-monitoring interface, with two forms: an initiation form, with patients' baseline characteristics, and an HIV seroconversion form. Univariate and adjusted multivariate analysis using a logistic regression model were performed to identify baseline factors associated with on-demand PrEP regimen prescription.<bold>Results: </bold>From 4 January 2016 to 28 February 2017, 3405 subjects were enrolled, with 2774 initiation forms completed; 98.1% were male and 96.9% were MSM. An on-demand regimen was prescribed to 57% of subjects. Older age (OR for participants older than 50 years = 1.76, 95% CI 1.35-2.3, P < 0.001) and site of prescription (OR of former IPERGAY sites = 2.28, 95% CI 1.84-2.83, P < 0.001) were associated with on-demand prescription. Those reporting sexually transmitted infection (STI) and condomless anal sex with at least two different partners were less likely to receive on-demand PrEP (OR = 0.68, 95% CI 0.57-0.82 and 0.75, 95% CI 0.57-0.98, respectively; P < 0.05 for all). Four breakthrough HIV infections were reported during the study, in the context of PrEP interruption or acute infection at the time of PrEP initiation.<bold>Conclusions: </bold>In a real-life setting in France, PrEP was used, either daily or on-demand, mostly by MSM, with breakthrough infections being rare. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
03057453
Volume :
74
Issue :
9
Database :
Complementary Index
Journal :
Journal of Antimicrobial Chemotherapy (JAC)
Publication Type :
Academic Journal
Accession number :
138251744
Full Text :
https://doi.org/10.1093/jac/dkz220